{"id":6254,"date":"2022-03-29T12:34:56","date_gmt":"2022-03-29T12:34:56","guid":{"rendered":"https:\/\/live-cancer-factfinder.pantheonsite.io\/fact-finder-tool\/terapi-ranplasman-omon-hrt\/"},"modified":"2026-10-20T16:30:53","modified_gmt":"2026-10-20T16:30:53","slug":"terapi-ranplasman-omon-hrt","status":"publish","type":"post","link":"https:\/\/cancerfactfinder.org\/ht\/zouti-pou-cheche-enfomasyon\/terapi-ranplasman-omon-hrt\/","title":{"rendered":"AFIKASYON: Terapi ranplasman \u00f2m\u00f2n (HRT) lak\u00f2z kans\u00e8"},"content":{"rendered":"\n

Sa ou ka tande<\/h2>\n\n

Fanm ki pran terapi ranplasman \u00f2m\u00f2n gen plis risk pou yo devlope kans\u00e8 nan tete. <\/span><\/p>\n\n

Sa syans di nou<\/h2>\n\n

Gen plizy\u00e8 kalite terapi ranplasman ormon (HRT), tankou estwoj\u00e8n s\u00e8lman, estwoj\u00e8n + pwojestin (konbine), oswa terapi ranplasman ormon byo-idantik.<\/span><\/p>\n\n

Estwoj\u00e8n<\/b> Pandan ke terapi ranplasman \u00f2m\u00f2n ak estwoj\u00e8n s\u00e8lman amelyore sent\u00f2m menopoz epi li ka diminye risk kans\u00e8 nan tete nan moun ki pa gen istwa kans\u00e8 nan tete nan fanmi yo, li ogmante risk kans\u00e8 andometryal (pawa matris la) (<\/span> ACS<\/span><\/a> ). Risk pou kans\u00e8 andometryal rete pi wo pase n\u00f2mal menm apre terapi a fini.<\/span><\/p>\n\n

Estwoj\u00e8n + pwojestin (konbine)<\/b> Ou kapab trete sent\u00f2m menopoz tou ak terapi estwoj\u00e8n ak pwojestin, ke yo rele terapi \u00f2m\u00f2n konbine. Plis yo itilize HRT a pou lontan, se plis risk la wo. Risk la retounen nan n\u00f2mal nan twa zan apre yo fin sispann \u00f2m\u00f2n yo, kidonk gen yon benefis pou sispann HRT a si yon fanm deja k\u00f2manse tretman an.<\/span> <\/p>\n\n

Terapi \u00f2m\u00f2n byoidantik<\/b> Terapi \u00f2m\u00f2n sa a itilize \u00f2m\u00f2n ki gen estwoj\u00e8n ak pwojestew\u00f2n ki gen menm estrikti chimik ak sa yo ki jwenn natir\u00e8lman nan k\u00f2 a.<\/span> <\/p>\n\n

Pr\u00e8v Epidemyolojik<\/h3>\n\n

Pwogestin ki nan terapi ormon konbine a diminye risk kans\u00e8 andometriyal ke estwoj\u00e8n ta bay. Sepandan, etid Women’s Health Initiative la te montre ke fanm ki itilize terapi ormon konbine gen yon risk ki pi wo pou kans\u00e8 nan tete ak kans\u00e8 nan ov\u00e8 (<\/span> NCI<\/span><\/a> ). Menm jan an tou, etid Million Women Study la te jwenn yon ogmantasyon nan risk kans\u00e8 nan tete pou terapi konbinezon estwoj\u00e8n ak pwogestin lan (<\/span> Clarkson et al.<\/span><\/a> ).<\/span><\/p>\n\n

Malgre ke terapi \u00f2m\u00f2n byo-idantik la vann k\u00f2m yon alt\u00e8natif ki pi an sekirite, pa gen okenn etid ki montre ke fanm k ap pran \u00f2m\u00f2n byo-idantik yo gen mwens ef\u00e8 segond\u00e8 grav (<\/span> NCI<\/span><\/a> ). \u00d2m\u00f2n byo-idantik yo gen menm risk pou sante ak nenp\u00f2t l\u00f2t kalite terapi \u00f2m\u00f2n.<\/span><\/p>\n\n

Pr\u00e8v toksikolojik\/Pr\u00e8v sip\u00f2<\/h3>\n\n

Etid ki egzamine enpak terapi ormonal sou makak ak sourit yo montre ke administrasyon estwoj\u00e8n + pwojestin ogmante risk kans\u00e8 nan tete (<\/span> Clarkson et al.<\/span><\/a> )<\/span> .<\/p>\n\n

Klasifikasyon kanseroj\u00e8n IARC: <\/span><\/h3>\n\n

Gwoup 1 (kanseroj\u00e8n pou moun)<\/span><\/p>\n\n

Kijan pou diminye risk ou<\/h2>\n\n

Nenp\u00f2t desizyon pou itilize estwoj\u00e8n, kit se poukont li kit se an konbinezon av\u00e8k yon terapi pwojestin, se chak fanm ak dokt\u00e8 li ki ta dwe pran li apre yo fin peze risk ak benefis yo (<\/span> SCA<\/span><\/a> ). Gen k\u00e8k bagay pou konsidere tankou risk debaz pou kans\u00e8 nan tete, andometriyal, ak ov\u00e8 (epi kijan terapi ormonal ka afekte sa); risk pou l\u00f2t kondisyon grav ki afekte pa terapi ormonal (egzanp: maladi k\u00e8, konjesyon serebral, gwo boul nan san, ak ef\u00e8 sou s\u00e8vo a); epi ki l\u00f2t medikaman yo ka itilize pou trete osteyopowoz oswa sent\u00f2m menopoz. Si yo pran desizyon pou pran terapi ormonal k\u00f2m tretman (HRT), li pi bon pou itilize li nan d\u00f2z ki pi ba a, pou yon pery\u00f2d osi kout ke posib, epi pou kontinye w\u00e8 dokt\u00e8 w regily\u00e8man pou yo ka siveye w pou ef\u00e8 segond\u00e8 yo (<\/span> SCA<\/span><\/a> ).<\/span><\/p>\n\n

N\u00f2t: Tout fanm ta dwe rap\u00f2te nenp\u00f2t senyen nan vajen ki rive apre menopoz touswit; li ka yon siy kans\u00e8 andometriyal. Menm si risk ou pa wo, ou toujou gen yon chans pou ou gen kans\u00e8 andometriyal. <\/span><\/p>\n\n

Liy final la<\/h2>\n\n

Terapi ormonal sibit (THS) ka ogmante risk ou genyen pou kans\u00e8 nan tete, andometri, ak\/oswa ov\u00e8. Pale ak dokt\u00e8 w anvan w pran yon desizyon sou terapi ranplasman ormonal. <\/p>\n","protected":false},"excerpt":{"rendered":"

Sa ou ka tande Fanm ki pran terapi ranplasman \u00f2m\u00f2n gen plis risk pou yo devlope kans\u00e8 nan tete. Sa syans di nou Gen plizy\u00e8 kalite terapi ranplasman ormon (HRT), tankou estwoj\u00e8n s\u00e8lman, estwoj\u00e8n + pwojestin (konbine), oswa terapi ranplasman ormon byo-idantik. Estwoj\u00e8n Pandan ke terapi ranplasman \u00f2m\u00f2n ak estwoj\u00e8n s\u00e8lman amelyore sent\u00f2m menopoz epi…<\/p>\n","protected":false},"author":1,"featured_media":6255,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[522],"tags":[472],"class_list":["post-6254","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pwoblem-medikal-oswa-tretman","tag-definitivman-oswa-pwobableman-vre"],"acf":[],"_links":{"self":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts\/6254","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/comments?post=6254"}],"version-history":[{"count":9,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts\/6254\/revisions"}],"predecessor-version":[{"id":18125,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/posts\/6254\/revisions\/18125"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/media\/6255"}],"wp:attachment":[{"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/media?parent=6254"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/categories?post=6254"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cancerfactfinder.org\/ht\/wp-json\/wp\/v2\/tags?post=6254"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}